Avenue Therapeutics Inc (ATXI) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Avenue Therapeutics Inc $0.53, price $0.36, upside +47.2%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Avenue Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.1500 – $2,981 · fair‑value band $0.3500 – $0.6700 · the $0.3600 price screens below the $0.5300 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Avenue Therapeutics in your weekly email
Every Wednesday you see whether Avenue Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain.
Show more
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Stock analysis
Avenue Therapeutics Inc (ATXI) currently trades at $0.3600, while our model-based Fair Value estimate is $0.5300, implying the stock looks roughly 32.1% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $0.3500 (bear) to $0.6700 (bull), the price of $0.3600 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Avenue Therapeutics Inc reported revenue of $1.4M in FY2025 versus $0 in FY2021. Reported net income was −$2.9M in FY2025.
Key figures
Market cap $2.0M · EPS (TTM) $−0.8600 · Return on equity −165% · Return on assets (EBIT) −306% · EPS growth (YoY) +67.0% · Free cash flow −$1.8M · Net cash $2.9M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
The share trades about 61% below its 52-week high and 140% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 47%, ATXI screens cheaper than that median.
Fair Value models
Bear $0.3500Fair Value $0.5300Bull $0.6700
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Avenue Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 5/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score52 · Above median
Fair Value upside+47% · Top 25%
Profitability
Return on assets−63% · Bottom 25%
Operating margin (TTM)0% · Above median
Growth and dividend
Revenue growth0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Avenue Therapeutics Inc (ATXI) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.5300 versus a price of $0.3600, about +47% upside (undervalued).
What is the fair value of ATXI?
Our model-based fair value for Avenue Therapeutics Inc is $0.5300 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.3600.
What is the quality score of ATXI?
Avenue Therapeutics Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Avenue Therapeutics Inc (ATXI)?
Our model-based price target is the fair value of $0.5300 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.3500, optimistic scenario $0.6700. It is a calculation from audited fundamentals, not an analyst target.
What is the Avenue Therapeutics Inc stock forecast for 2026?
Our models put fair value at $0.5300, about +47% upside versus a price of $0.3600 (undervalued). Cautious scenario $0.3500, optimistic scenario $0.6700. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Avenue Therapeutics Inc (ATXI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Avenue Therapeutics Inc it is $0.5300 per share (as of Sep 24, 2026), against a price of $0.3600. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Avenue Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ATXI trades below its calculated fair value: price $0.3600, fair value $0.5300, a gap of about +47% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATXI?
No. The price is what the market pays today ($0.3600); the fair value is what the company's own numbers justify ($0.5300). For Avenue Therapeutics Inc the two are $0.1700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Avenue Therapeutics Inc worth?
The market values Avenue Therapeutics Inc at about $2.0M (market capitalisation, as of Sep 24, 2026). Per share that is $0.3600; our models calculate a fair value of $0.5300 per share.
What do the bullish and bearish scenarios say about ATXI?
Our models span a range for Avenue Therapeutics Inc: cautious scenario $0.3500, base $0.5300, optimistic $0.6700 per share (as of Sep 24, 2026, price $0.3600). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Avenue Therapeutics Inc (ATXI)?
Balance-sheet figures for Avenue Therapeutics Inc (as of Sep 24, 2026): return on equity −164.8%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is ATXI from its 52-week high?
Avenue Therapeutics Inc trades at $0.3600, about 61% below its 52-week high of $0.9258 and 140% above the low of $0.1500 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5300 is for.
Which stocks are comparable to Avenue Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Avenue Therapeutics Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $0.3600, calculated fair value $0.5300 (+47%), Quality Score 51/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ATXI calculated?
We run Avenue Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.5300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Avenue Therapeutics Inc currently trades 47 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Avenue Therapeutics Inc (ATXI)?
The closing price on Sep 23, 2026 was $0.3600. Our model-based fair value is $0.5300, about +47% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Avenue Therapeutics Inc right now?
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($0.3500 to $0.6700) leaves room in how you read the outcome.
Key figures of Avenue Therapeutics Inc
How large is the market capitalisation of Avenue Therapeutics Inc (ATXI)?
The market capitalisation of Avenue Therapeutics Inc is $2.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Avenue Therapeutics Inc (ATXI)?
Earnings per share at Avenue Therapeutics Inc are $−0.8600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Avenue Therapeutics Inc (ATXI)?
The return on equity (ROE) of Avenue Therapeutics Inc is −165% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Avenue Therapeutics Inc (ATXI)?
On an EBIT basis the return on assets of Avenue Therapeutics Inc is −306% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast are earnings growing at Avenue Therapeutics Inc (ATXI)?
Earnings per share at Avenue Therapeutics Inc are growing +67.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Avenue Therapeutics Inc (ATXI) generate?
The free cash flow of Avenue Therapeutics Inc is −$1.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Avenue Therapeutics Inc (ATXI) hold?
Avenue Therapeutics Inc holds more cash than debt, $2.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Avenue Therapeutics Inc in the live analysis
One click puts Avenue Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026